The Pathogenesis of Neural Injury in Animal Models of the Antiphospholipid Syndrome

被引:38
|
作者
Katzav, Aviva [1 ,2 ]
Shoenfeld, Yehuda [3 ,4 ]
Chapman, Joab [1 ,2 ]
机构
[1] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Med B, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[4] Chaim Sheba Med Ctr, Dept Res, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
基金
以色列科学基金会;
关键词
Antiphospholipid syndrome; Antiphospholipid antibodies; Neurology; Behavior; Dementia; Epilepsy; Chorea; Animal models; ANTI-BETA(2)-GLYCOPROTEIN I ANTIBODIES; ACTIVATED PROTEIN-KINASE; COGNITIVE DEFICITS; HUGHES-SYNDROME; THROMBIN INHIBITION; ENDOTHELIAL-CELLS; PREGNANT RABBITS; TISSUE FACTOR; MOUSE MODEL; BRAIN;
D O I
10.1007/s12016-009-8154-x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Circulating antiphospholipid antibodies (aPL) are associated with central nervous system dysfunction in antiphospholipid syndrome (APS) patients and in a mouse model of APS. We propose a logical pathway of how experimental APS (eAPS) causes brain dysfunction: binding of the antibodies to the brain endothelium evoking microthrombosis, endothelial dysfunction, and IgG leakage through the blood-brain barrier (BBB), then secondary inflammatory cell spread around blood vessels and production of cytokines by these inflammatory cells leading to further disruption of the BBB. The diffuse brain endothelial dysfunction would result in extravasation of serum proteins including APS IgG and activated thrombin, which may induce the behavioral changes observed in the APS mice. We have collected data from the mouse eAPS model which supports this hypothesis. Elucidating the mechanism of the pathogenicity of aPL in vitro and in vivo will serve as a much needed basis for developing new therapeutic modalities in this important disorder.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 50 条
  • [41] INDUCTION AND PATHOGENESIS OF ANTIPHOSPHOLIPID ANTIBODY (APA) SYNDROME
    GILMANSACHS, A
    WONG, D
    WESTERMAN, MP
    KUCUK, O
    BEAMAN, KD
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A72 - A72
  • [42] Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
    Knight, Jason S.
    Branch, D. Ware
    Ortel, Thomas L.
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [43] The Role of the Gut Microbiota in the Pathogenesis of Antiphospholipid Syndrome
    Ruff, William E.
    Vieira, Silvio M.
    Kriegel, Martin A.
    CURRENT RHEUMATOLOGY REPORTS, 2015, 17 (01)
  • [44] Antiphospholipid antibody syndrome - A review of pathogenesis and treatment
    Fong, KY
    Boey, ML
    CLINICAL IMMUNOTHERAPEUTICS, 1996, 6 (03): : 228 - 237
  • [45] Antiphospholipid Syndrome nephropathy: From Pathogenesis to Treatment
    Tektonidou, Maria G.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [46] SYNDROME OF ANTIPHOSPHOLIPID ANTIBODIES PATHOGENESIS AND CLINICOMORPHOLOGICAL MANIFESTATIONS
    ZEBRINO, DD
    LUKASEVICH, LL
    BILYNSKAYA, OA
    ARKHIV PATOLOGII, 1990, 52 (04) : 65 - 69
  • [47] Prolactin's role in the pathogenesis of the antiphospholipid syndrome
    Praprotnik, S.
    Agmon-Levin, N.
    Porat-Katz, B. S.
    Blank, M.
    Meroni, P. L.
    Cervera, R.
    Miesbach, W.
    Stojanovich, L.
    Szyper-Kravitz, M.
    Rozman, B.
    Tomsic, M.
    Shoenfeld, Y.
    LUPUS, 2010, 19 (13) : 1515 - 1519
  • [48] Clinical features and pathogenesis of catastrophic antiphospholipid syndrome
    Kaburaki, J
    INTERNAL MEDICINE, 2000, 39 (10) : 763 - 764
  • [49] The Role of the Gut Microbiota in the Pathogenesis of Antiphospholipid Syndrome
    William E. Ruff
    Silvio M. Vieira
    Martin A. Kriegel
    Current Rheumatology Reports, 2015, 17
  • [50] Animal models of papillomavirus pathogenesis
    Campo, MS
    VIRUS RESEARCH, 2002, 89 (02) : 249 - 261